ReviewAnnals of the New York Academy of Sciences2012
Cardiovascular defense challenges at the basic, clinical, and population levels.
Review in Annals of the New York Academy of Sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Contemporary Challenges of Regenerative Therapy in Patients with Ischemic and Non-Ischemic Heart Failure.Journal of cardiovascular development and disease · 2022Review
- Exercise, oxidants, and antioxidants change the shape of the bell-shaped hormesis curve.Redox biology · 2017Article
- Endpoints in stem cell trials in ischemic heart failure.Stem cell research & therapy · 2015Review
- Top 10 cardiovascular therapies and interventions for the next decade.Nature reviews. Cardiology · 2014Review
- Conceptual heuristic models of the interrelationships between obesity and the occupational environment.Scandinavian journal of work, environment & health · 2013Review
- Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.Vascular health and risk management · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cardiovascular disease (CVD) is now the leading cause of mortality worldwide. Particularly in low and middle income countries, rapid urbanization and secondary factors, such as increasing obesity, poor diet, and lack of exercise, have combined to propel CVD into this position. Given the enormous scope of this problem and the complex cultural, societal, and political issues that are involved, an equally sophisticated and multipronged approach is required to combat CVD at the global level. In this review, we outline the basic, clinical, and population level challenges that we face in defending ourselves against this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.